Valuence Merger Corp. I 10-K — AI Bull & Bear Analysis

The 10-K filing reveals a company at a crossroads, transitioning from a traditional SPAC to a micro-float acquisition vehicle. While the reduction in public shares removes the 'redemption risk' that plagued many 2021-era SPACs, it has left the company with a fragile operational base. The tension between the high per-share trust value and the lack of unrestricted working capital creates a binary outcome for investors: either a high-conviction merger is announced shortly, or the company drifts toward a mandatory liquidation by March 2027. Ultimately, the filing underscores a high-stakes bet on management's ability to execute a cross-border deal under extreme time pressure. The delisting from Nasdaq has stripped away institutional liquidity, leaving the stock as a pure play on the trust value and the possibility of a breakthrough Asian biotech merger. Investors are essentially weighing the pedigree of the sponsor against the stark reality of a $4.96 million working capital deficit.